Sickle cell anemia (SCA) is a serious blood disorder affecting many newborns, especially in Africa. Many children with SCA die young due to lack of care. Hydroxyurea is a medicine that can help treat SCA when taken daily. It works well in countries with better resources, but in Africa, it's hard to use because it needs frequent lab tests and the right dose is tricky to find. This study in Africa, called the PUSHUP trial, wants to make hydroxyurea safer and easier to use. They will test it on 400 children in Angola using smart machines and computer programs to find the best dose with fewer tests.

Key Points:

• Study involves 400 children aged 6 months to 12 years in Angola.
• Participants will get personalized doses of hydroxyurea with minimal lab monitoring.
• Eligible children must not have used hydroxyurea or had a blood transfusion in the last 6 months.